Achieving health equity in bladder cancer care: Addressing disparities through collaborative research and evidence-based strategies.

IF 1.2 4区 医学 Q4 ONCOLOGY Bladder Cancer Pub Date : 2024-12-23 eCollection Date: 2024-12-01 DOI:10.1177/23523735241289237
Yelba Castellon-Lopez, Patricia A Thompson
{"title":"Achieving health equity in bladder cancer care: Addressing disparities through collaborative research and evidence-based strategies.","authors":"Yelba Castellon-Lopez, Patricia A Thompson","doi":"10.1177/23523735241289237","DOIUrl":null,"url":null,"abstract":"<p><p>The United States has seen a decrease in the incidence of bladder cancer and a decline in mortality rates over the past 20 years. However, not all groups have benefited equally from this trend. The American Association of Community Cancer Centers (ACCC) has issued ten strategies to improve cancer care delivery for underserved patient populations. Unfortunately, the evidence supporting the best methods for reducing disparities in different patient groups and care delivery settings remains severely limited. In this short communication, using a personalized narrative woven into a clinical case, we highlight the need for more research on bladder cancer care delivery to ensure that significant investments in precision oncology translate into genuine improvements for all patients diagnosed with bladder cancer.</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"10 4","pages":"264-269"},"PeriodicalIF":1.2000,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864232/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bladder Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/23523735241289237","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The United States has seen a decrease in the incidence of bladder cancer and a decline in mortality rates over the past 20 years. However, not all groups have benefited equally from this trend. The American Association of Community Cancer Centers (ACCC) has issued ten strategies to improve cancer care delivery for underserved patient populations. Unfortunately, the evidence supporting the best methods for reducing disparities in different patient groups and care delivery settings remains severely limited. In this short communication, using a personalized narrative woven into a clinical case, we highlight the need for more research on bladder cancer care delivery to ensure that significant investments in precision oncology translate into genuine improvements for all patients diagnosed with bladder cancer.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
实现膀胱癌护理的健康公平:通过合作研究和循证战略解决差异。
在过去的20年里,美国的膀胱癌发病率有所下降,死亡率也有所下降。然而,并不是所有的群体都同样受益于这一趋势。美国社区癌症中心协会(ACCC)发布了十项策略,以改善服务不足的患者群体的癌症护理服务。不幸的是,支持减少不同患者群体和护理环境差异的最佳方法的证据仍然非常有限。在这篇简短的文章中,我们通过一个临床病例的个性化叙述,强调了对膀胱癌护理提供进行更多研究的必要性,以确保在精准肿瘤学方面的重大投资转化为对所有膀胱癌诊断患者的真正改善。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Bladder Cancer
Bladder Cancer Medicine-Urology
CiteScore
1.60
自引率
0.00%
发文量
35
期刊介绍: Bladder Cancer is an international multidisciplinary journal to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis and treatment of tumors of the bladder and upper urinary tract. The journal publishes research reports, reviews, short communications, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that expedites our fundamental understanding and improves treatment of tumors of the bladder and upper urinary tract.
期刊最新文献
Patterns of care and associated social determinants of health in the definitive treatment of localized muscle-invasive bladder cancer patients. Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab. Adjuvant immunotherapy for muscle-invasive urothelial carcinoma: Considerations for targeting patients. Analysis of sarcopenia indicators on survival prediction undergoing radical cystectomy. Circulating tumor DNA-guided adjuvant immunotherapy in muscle-invasive bladder cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1